Study/Projects by Year (2019)

Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)

Post Date: 
2019-12-30
Learn more about this effort to foster development of long-lasting therapies for illnesses that require taking medications long-term

Increasing Market and Public Health Outcomes Through Scaling Up Affordable Access Models of Short Course Preventive Therapy for TB (IMPAACT4TB)

Post Date: 
2019-12-17
   |   
Countries: 
   |   
Clinical Sites: 
Primary Objective: This study is being conducted in Brazil, Cambodia, China, Ethiopia, Ghana, Haiti, India, Indonesia, Kenya, Malawi, Mozambique, South Africa, Tanzania, and Zimbabwe. The overall goal is to reduce TB incidence among (1) people living with HIV who are on antiretroviral therapy, and...

Markers of Lung Impairment in HIV-TB Coinfected Indian Adults

Post Date: 
2019-12-11
   |   
Countries: 
   |   
Clinical Sites: 
Objectives/Aims We will compare the degree of lung impairment between HIV-TB co-infected adults (HIV-TB group) and TB cases without HIV co-infection (TB group) who successfully complete TB therapy. We hypothesize that the HIV-TB group will have a greater degree of lung...

T Cell Biomarkers and T-regulatory Responses to Pediatric TB

Post Date: 
2019-11-21
   |   
Countries: 
   |   
Clinical Sites: 
The goals of this study are to: Validate host T cell biomarkers for diagnosis of pediatric TB Investigate the phenotype and functions of T-regulatory cells in pediatric TB We will use cryopreserved PBMC samples from CTRIUMPH cohorts: Pediatric unconfirmed TB, confirmed TB, latest Tb, and no TB...

Inflammasome Genetics and Tuberculosis Treatment Outcomes

Post Date: 
2019-11-07
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Amita Gupta is a Co-PI on this study. STUDY DESIGN We will conduct a retrospective case-cohort study nested within the CTRIUMPH and EDOTS cohorts to address our study objectives. This will enable us to measure the association of polymorphisms with multiple clinical outcomes simultaneously and...

A Phase 2a, Double-Blind, Placebo-Controlled, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of ID93 + GLA-SE Vaccine Administered to HIV-Negative Patients at 3 Time Points During Multidrug Therapy for Drug Susceptible Pulmonary TB

Post Date: 
2019-10-28
   |   
Clinical Sites: 
This study was terminated in April 2020. Vidya Mave was PI of this HIV vaccine trial. BACKGOUND: Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis (Mtb). TB is one of the leading causes of morbidity and mortality around the world with an estimated 10...

Utility of Multiplexed Rapid Fever Panel Kit among Hospitalized Febrile Patients in India and Its Impact on Antimicrobial Use and Diagnosis

Post Date: 
2019-10-24
Introduction Easy to use and multiplex diagnostic tools are needed to identify common causes of fever caused by vector-borne infectious diseases. Chembio has developed dual path platform (DPP) technology which differs from traditional lateral flow rapid diagnostic tests (RDT) by separating the...

Evaluation of a Urinary Biomarker Assay for Diagnosis and Test of Cure for Tuberculosis

Post Date: 
2019-09-09
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Jeff Tornheim is PI of this study. METHODS This study will make use of biorepository samples from the Cohort for TB Research by the Indo-US Medical Partnership (CTRIUMPh). CTRIUMPh, funded by the US NIH and Indian Department of Biotechnology, is an academic collaboration between Johns Hopkins...

A5300B/I2003B: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx)

Post Date: 
2019-08-19
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Amita Gupta is Protocol Co-chair for this multinational clinical trial. BACKGROUND The World Health Organization (WHO) estimates that there were 480,000 incident cases of MDR-TB globally in 2015. MDR-TB has been shown to be almost twice as common in TB...

A5300B/I2003B: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx)

Post Date: 
2019-08-19
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Amita Gupta is Protocol Co-chair for this multinational clinical trial. BACKGROUND The World Health Organization (WHO) estimates that there were 480,000 incident cases of MDR-TB globally in 2015. MDR-TB has been shown to be almost twice as common in TB...

Management of Multidrug-resistant Tuberculosis among ART Programs in Low- and Middle-income Countries within the Global IeDEA Network

Post Date: 
2019-07-22
This study was terminated effective: 6/9/2022 Purpose The purpose of the IeDEA MDR-TB survey is to study the clinical management of HIV patients co-infected with MDR-TB or XDR-TB from the perspective of healthcare workers in ART programs participating in the IeDEA global cohort consortium...

Visual Field Loss in HIV-Positive Patients of Non-Infectious HIV Retinopathy

Post Date: 
2019-06-02
   |   
Countries: 
   |   
Clinical Sites: 
New study will assess HIV+ patients and determine the prevalence of visual field loss due to noninfectious HIV retinopathy

Immune Correlates of LTBI in HIV-exposed Infants

Post Date: 
2019-04-29
   |   
Countries: 
About 2 billion people worldwide harbor asymptomatic latent TB infection (LTBI), activation of which results in progression to TB disease. In areas of high tuberculosis (TB) prevalence, infants and young children have a 3-fold higher risk of progression and death from TB at age < 5 years...

P2010: Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants “VESTED”

Post Date: 
2019-02-06
   |   
Countries: 
   |   
Clinical Sites: 
This study was terminated September 2, 2021 Full Title: P2010: Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants “...